Lilly(LLY) - 2024 Q1 - Quarterly Results

April 30, 2024 For Release: Immediately Refer to: Jordan Bishop; jordan.bishop@lilly.com; (317) 473-5712 (Media) Joe Fletcher; jfletcher@lilly.com; (317) 296-2884 (Investors) Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum • Revenue in Q1 2024 increased 26%, driven by Mounjaro, Zepbound, Verzenio and Jardiance. • Pipeline progress included positive results from two Phase 3 trials of tirzepatide for obstructive sleep apnea; ...